Published in Br J Haematol on October 14, 2014
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia. Oncotarget (2016) 0.78
Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. Bone Marrow Transplant (2016) 0.76
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review. Ont Health Technol Assess Ser (2016) 0.75
Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A (2017) 0.75
When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia. J Clin Med (2017) 0.75
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Parkinson's disease. Lancet (2009) 6.60
Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med (2009) 6.31
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer (2010) 3.44
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13
Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet (2011) 3.05
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain (2005) 2.67
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol (2012) 2.59
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Significant small-bowel lesions detected by alternative diagnostic modalities after negative capsule endoscopy. Gastrointest Endosc (2008) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res (2009) 2.29
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain (2010) 2.19
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. Blood (2002) 2.15
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain (2008) 2.13
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol (2005) 2.06
Proteomic analysis of the Arabidopsis nucleolus suggests novel nucleolar functions. Mol Biol Cell (2004) 2.02
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol (2006) 1.96
Are bowel purgatives and prokinetics useful for small-bowel capsule endoscopy? A prospective randomized controlled study. Gastrointest Endosc (2009) 1.95
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2011) 1.79
The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev (2009) 1.79
Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst (2006) 1.76
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord (2012) 1.75
The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology (2013) 1.74
Neuropathological findings in benign tremulous parkinsonism. Mov Disord (2012) 1.74
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood (2007) 1.72
Endoscopic mucosal resection of 161 cases of large sessile or flat colorectal polyps. Scand J Gastroenterol (2007) 1.71
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol (2003) 1.70
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend (2007) 1.64
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A (2004) 1.57
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.57
Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol (2011) 1.57
Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev (2006) 1.57
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging (2010) 1.56
Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord (2007) 1.52
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain (2007) 1.52
Structure and function of the nucleolus in the spotlight. Curr Opin Cell Biol (2006) 1.51
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood (2003) 1.49
Umbilical cord blood banking: public good or private benefit? Med J Aust (2008) 1.49
New insights into nucleolar architecture and activity. Int Rev Cytol (2006) 1.48
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res (2008) 1.47
Neurofibromatosis type 1 and multiple primary malignancies. Med Pediatr Oncol (2003) 1.45
Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol (2013) 1.41
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet (2011) 1.41
A critical analysis of the effect of view mode and frame rate on reading time and lesion detection during capsule endoscopy. Dig Dis Sci (2015) 1.41
Flat colorectal neoplasms and the impact of the revised Vienna Classification on their reporting: a case-control study in UK and Japanese patients. Scand J Gastroenterol (2006) 1.41
Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med (2007) 1.40
Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment : a retrospective and a prospective study. Support Care Cancer (2012) 1.40
Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res (2007) 1.40
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood (2010) 1.39
Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet (2007) 1.38
A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther (2006) 1.36
Aberrant mRNA transcripts and the nonsense-mediated decay proteins UPF2 and UPF3 are enriched in the Arabidopsis nucleolus. Plant Cell (2009) 1.35
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med (2010) 1.35
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain (2010) 1.34
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood (2013) 1.34
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol (2006) 1.31
The p53 pathway and its inactivation in neuroblastoma. Cancer Lett (2003) 1.29
Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life (2007) 1.27
Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol (2011) 1.27